Human donor bone marrow cells can enhance hyporeactivity in renal transplantation using maintenance FK 506 and OKT3 induction therapy.
Ciancio
G
G
Department of Surgery, University of Miami School of Medicine, Florida 33101, USA.
Carreno
M
M
Mathew
J
J
Ricordi
C
C
Garcia
R
R
Karatzas
T
T
Fuller
L
L
Cirocco
R
R
Burke
G
G
Webb
M
M
Nery
J
J
Tzakis
A
A
Roth
D
D
Esquenazi
V
V
Miller
J
J
D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D005434:Flow Cytometry; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000473:pathology / Q000517:prevention & control; D006650:Histocompatibility Testing; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology; D007959:Lymphocyte Culture Test, Mixed; D008212:Lymphocyte Depletion; D008775:Methylprednisolone / Q000627:therapeutic use; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D016559:Tacrolimus / Q000627:therapeutic use*; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016559:Tacrolimus; D008775:Methylprednisolone